Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Papp

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
The British Journal of Dermatology|February 15, 2017
Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumabJ Bagel, S Tyring, K C Rice, et al.
The British Journal of Dermatology|July 17, 2016
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trialR Bissonnette, K A Papp, Y Poulin, et al.
The British Journal of Dermatology|October 31, 2012
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyK A Papp, R G Langley, B Sigurgeirsson, et al.
The British Journal of Dermatology|June 14, 2005
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionK A Papp, S Tyring, M Lahfa, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 10, 2020
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studiesJ F Merola, K A Papp, P Nash, et al.
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2019
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28K A Papp, K Reich, A Blauvelt, et al.
The British Journal of Dermatology|May 10, 2018
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trialsA Blauvelt, K Reich, K A Papp, et al.
The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.
The British Journal of Dermatology|June 11, 2017
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasisK A Papp, H Bachelez, A Blauvelt, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
The British Journal of Dermatology|February 15, 2017
Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumabJ Bagel, S Tyring, K C Rice, et al.
The British Journal of Dermatology|July 17, 2016
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trialR Bissonnette, K A Papp, Y Poulin, et al.
The British Journal of Dermatology|October 31, 2012
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyK A Papp, R G Langley, B Sigurgeirsson, et al.
The British Journal of Dermatology|June 14, 2005
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionK A Papp, S Tyring, M Lahfa, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 10, 2020
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studiesJ F Merola, K A Papp, P Nash, et al.
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2019
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28K A Papp, K Reich, A Blauvelt, et al.
The British Journal of Dermatology|May 10, 2018
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trialsA Blauvelt, K Reich, K A Papp, et al.
The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.
The British Journal of Dermatology|June 11, 2017
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasisK A Papp, H Bachelez, A Blauvelt, et al.
Pageof 6